Defying the odds: 30 years in AL amyloidosis research—recent barriers to clinical trial enrollment
Vaishali Sanchorawala(Boston Medical Center), Andrew Staron(Boston University), Tracy Joshi(Boston University), Anthony C Shelton, J. Mark Sloan(Boston University), Natasha Burke(Boston University), Elise Goetz(Boston University), Bruna Barroso(Boston University), Lisa Mendelson(Boston University)
Cited by 1
Related Papers
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study
|Annals of Internal Medicine|2004|615
Systemic immunoglobulin light chain amyloidosis
|Nature Reviews Disease Primers|2018|550